This blog using web news aggregating service called”news!eye”.
[Today’s pick up]
Biopsy Of Recurrent Breast Cancer Can Alter Treatment
http://www.sciencedaily.com/releases/2009/03/090318211238.htm
2009-03-19 11:38:09.0
Science Daily (press release)
18, 2009) ― For women with recurrent breast cancer, the treatment the doctor chooses is usually based on the properties of their original breast cancer. ...
[Articles about cancer treatment]
Studies raise doubts about prostate cancer test
http://www.startribune.com/lifestyle/health/41467212.html?elr=KArks7PYDiaK7DUvDE7aL_V_BD77:DiiUiD3aPc:_Yyc:aUU
2009-03-19 10:09:47.0
Minneapolis Star Tribune
Prostate cancer treatment can result in impotence and incontinence following surgery, and, at times, painful defecation or chronic diarrhea following ...
PSA - the results are in
http://www.6minutes.com.au/articles/z1/view.asp?id=473814
2009-03-19 12:38:09.0
6minutes
However the study authors said benefits of screening may have been masked by recent improvements in prostate cancer treatment, or may be more evident after ...
Medivation Cleared to Begin Pivotal Prostate Cancer Trial
http://www.bioworld.com/servlet/com.accumedia.web.Dispatcher?next=bioWorldHeadlines_article&forceid=50369
2009-03-19 12:38:09.0
BioWorld Online
... patient enrollment this year, will involve about 1200 patients with metastatic castration-resistant prostate cancer who have failed docetaxel treatment. ...
Roche submits Tarceva for non-small cell lung cancer
http://www.reuters.com/article/rbssHealthcareNews/idUSLJ37763420090319
2009-03-19 15:38:26.0
Reuters
... showed that treatment with Tarceva, or Erlotinib, delays the progression of non-small cell lung cancer when given immediately following chemotherapy. ...
Research and Markets Adds Report: US Breast Cancer Therapeutics ...
http://www.tradingmarkets.com/.site/news/Stock%20News/2229861/
2009-03-19 15:38:26.0
Trading Markets (press release)
With increasing public awareness about breast cancer and its treatment, the market for breast cancer therapeutics is primed for expansion. ...
No comments:
Post a Comment